HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Wall Street Zen

Key Points

• HUTCHMED has received a rating upgrade from Wall Street Zen, increasing its status from "buy" to "strong-buy" in a recent report.
• Other analysts have had mixed views, with HSBC downgrading HUTCHMED from "buy" to "hold," while Bank of America raised its price target to $28 and maintained a "buy" rating.
• A significant number of institutional investors have increased their stakes in HUTCHMED, with the Public Employees Retirement System of Ohio raising its position by nearly 50% in the last quarter.

HUTCHMED (NASDAQ:HCM - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also recently issued research reports about the company. HSBC cut HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Bank of America boosted their price objective on HUTCHMED from $27.00 to $28.00 and gave the company a "buy" rating in a report on Tuesday.

HUTCHMED Trading Down 1.0%

HCM opened at $17.61 on Friday. The business has a fifty day moving average of $15.59 and a 200 day moving average of $14.89. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.50. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.70 and a current ratio of 2.83.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Public Employees Retirement System of Ohio raised its position in HUTCHMED by 49.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after purchasing an additional 899 shares in the last quarter. Summit Trail Advisors LLC raised its position in HUTCHMED by 7.7% during the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock valued at $212,000 after purchasing an additional 1,004 shares in the last quarter. Barclays PLC raised its position in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after purchasing an additional 2,255 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of HUTCHMED by 23.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company's stock worth $233,000 after acquiring an additional 2,916 shares in the last quarter. Finally, Crossmark Global Holdings Inc. raised its position in shares of HUTCHMED by 31.4% in the 1st quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company's stock worth $367,000 after acquiring an additional 5,829 shares in the last quarter. 8.82% of the stock is owned by institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.